Actively Recruiting
Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients
Led by Royal Marsden NHS Foundation Trust · Updated on 2026-02-25
800
Participants Needed
1
Research Sites
345 weeks
Total Duration
On this page
Sponsors
R
Royal Marsden NHS Foundation Trust
Lead Sponsor
I
Institute of Cancer Research, United Kingdom
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a cohort study aimed at developing a stratified medicine approach for personalised neoadjuvant chemotherapy (NCT) in high-risk soft tissue sarcoma (STS) patients with dedifferentiated liposarcoma (DDLPS), leiomyosarcoma (LMS), synovial sarcoma (SS), vascular sarcomas, malignant peripheral nerve sheath tumour (MPNST) or other subtypes. It comprises of both retrospective and prospective tissue collection from patients advancing directly to surgery (control group) and patients receiving NCT and surgery.
CONDITIONS
Official Title
Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent for the prospective cohort
- Histopathological diagnosis of high-risk soft tissue sarcoma with subtypes including dedifferentiated liposarcoma, leiomyosarcoma, synovial sarcoma, vascular sarcomas, or malignant peripheral nerve sheath tumor; other subtypes allowed with principal investigator approval
- High-risk sarcoma defined as tumors larger than 5 cm or Grade 3
- Tumor located in a deep anatomic site
- Disease amenable to biopsy; patients not amenable to repeat biopsy may be considered by local site principal investigator
- Resectable tumor
- Measurable disease by RECIST 1.1
- Age 18 years or older
- WHO performance status 0 to 2
- For patients receiving NCT, medically fit with adequate organ function to undergo chemotherapy
- Medically fit to undergo surgical resection
- Capable of giving written informed consent (for prospective cohort) and able to comply with study schedule
- Patients may also participate in the STRASS 2 trial
You will not qualify if you...
- Prior invasive malignancy within the last 5 years, except low-risk malignancies reviewed by principal investigator
- Known additional malignancy that is progressing or requires active treatment
- Metastatic disease not suitable for curative intent local therapy
- Any active uncontrolled medical conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Royal Marsden Hospital
London, United Kingdom, SW3 6JJ
Actively Recruiting
Research Team
S
Stephanie Elston, MSc
CONTACT
T
Thuy-Giang Nguyen, BSc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here